Company intelligence
Apertura Gene Therapy
Bringing the Future of Gene Therapy into Focus
About Apertura Gene Therapy
Apertura is a biotechnology company opening opportunities in gene therapy for treating debilitating diseases with limited options. We are pioneering next-generation AAV gene therapies by simultaneously engineering capsids, regulatory elements, and payloads to overcome current limitations in genetic medicine. Founded on technologies from the Broad Institute and Harvard University, and with support from Deerfield Management Company, we are located at the Cure in New York City.
Verified activity
Signals from Apertura Gene Therapy
4 published signals
Presence & Recognition
Apertura Gene Therapy will be hosting the 2026 Advanced Therapies Europe Conference at the InterContinental Barcelona Hotel in Barcelona.
Reported by Apertura Gene Therapy
Presence & Recognition
Apertura Gene Therapy employee Jorge Santiago-Ortiz, Ph.D., will speak on enabling IV, brain-wide AAV gene delivery through an FDA-informed, GMP-ready platform at the 2026 Advanced Therapies Europe Conference in Barcelona on Tuesday, September 8.
Reported by Apertura Gene Therapy
Presence & Recognition
Apertura Gene Therapy employee Jorge Santiago-Ortiz, Ph.D., will serve as a panelist for a fireside chat titled AAV at scale without compromise at the 2026 Advanced Therapies Europe Conference in Barcelona following his presentation.
Reported by Apertura Gene Therapy
Presence & Recognition
Apertura Gene Therapy employee Jorge Santiago-Ortiz, Ph.D., is attending the 2026 Advanced Therapies Europe Conference in Barcelona.
Reported by Apertura Gene Therapy